Global Health and Pharma Magazine has named Umeå Biotech Incubator (UBI) as Europe’s most innovative biotechnology incubator in recognition of the positive changes it is making to the biotech industry.
“We are delighted to have been given this award, and that word of our innovative way of working has spread from Umeå to the whole of Europe. It’s really cool”, says Jennie Ekbeck, CEO of Umeå Biotech Incubator.
Nordic Biomarker is now moving to new, larger premises in Umestan. The premises are four times as large as the previous one and provide good opportunities for the company to continue growing.
Umeå-based biopharmaceutical company Lipum AB is raising capital for a listing on the Nasdaq First North Growth Market in the spring of 2021.
“We are taking the next exciting step in the company’s development”, says Lipum’s CEO Einar Pontén.
Three high school girls from Umeå have started a UF (Young Enterprise) company that hopes to encourage more girls to study technology and qualify to work in the tech industry.
The three students have already attracted the attention of a number of large technology companies in Umeå who share their ambition.
“We are delighted that several major technology companies believe in us. It shows they are willing to make an effort to create a gender-equal technology industry”, says Aja Tomic, one of the three UF company founders.
Lipigon Pharmaceuticals AB, which develops new treatments for lipid-related diseases, announces that the board has elected Urban Paulsson as the new chairman of the board. Paulsson was elected to the board on October 30, 2020 and now replaces Carina Schmidt, who requested her own resignation from the board.
Inficure Bio, based in Umeå in northern Sweden, has recently been granted a patent in the United States for its unique preclinical model. At the same time a study describing the basics of the model has been accepted for publication in respected online journal Scientific Reports.
“We are delighted and anticipate that thanks to this attention we will strengthen our position in the market and expect even more customers to show interest in our model”, says Sofia Mayans, CEO of Inficure Bio.
A new AI solution for sustainable production is to be tested at Diamyd Medical’s vaccine manufacturing facility in Umeå. It is hoped, once the solution has been refined, that it can be introduced in companies throughout Sweden.
“This represents a unique opportunity that we do not see that often in Sweden. We are happy to be working with recognised experts in both AI and sustainable production”, says Ulf Hannelius, CEO of Diamyd Medical.
Give your company’s sustainability effort a boost! Sign up for three effective workshops on circular entrepreneurship.
Umeå Biotech Incubator (UBI) has strengthened its board with the appointment of respected business profiles Anette Nordvall, named Sweden’s most powerful tech investor by DI Digital, and Camilla Huse Bondesson, who has extensive experience of marketing, sales and business development in the life science industry.
“We have been focused on finding people who can contribute with business acumen and an investor perspective so that we continue building a world-class incubator”, says Jennie Ekbeck, CEO of Umeå Biotech Incubator.
At an Extraordinary General Meeting, Urban Paulsson was elected a regular board member of Umeå-based Lipigon Pharmaceuticals AB. Urban Paulsson’s business law expertise entails a strengthening of the Board and is an important component for the company’s continued successful development.
Umeå-based life science company Inficure Bio is one of three companies from northern Sweden chosen to present their business cases at ‘Mötesplats Stockholm – The Great Northern Capital Connect’ in early 2021.
Prediktera from Umeå in northern Sweden has made the list of Europe’s most dynamic Artificial Intelligence (AI) startups.
“This increases our visibility and opportunities to find partners, employees and customers in Europe and around the world,” says Andreas Vidman, CEO of Prediktera.
Umeå Biotech Incubator (UBI) is one of the hosts of the Swedish Life Science Investor Meeting (24-25th November), a digital event that will bring biotech companies and potential international investors together.
“The COVID-19 pandemic has caused untold problems for businesses, but one advantage it has given life science companies is the opportunity to meet international investors who may not have necessarily visited Sweden otherwise. Thanks to digital technology we can now reach out further than ever before”, says Jennie Ekbeck, CEO of Umeå Biotech Incubator.
Fredrik Almqvist, CEO of QureTech Bio based in Umeå in northern Sweden, is among thousands of researchers hoping to draw attention to the challenges of antibiotic resistance as part of World Antibiotic Awareness Week (18-24 November).
“It’s a problem that’s comparable to the climate crisis. We have to find new ways to kill antibiotic resistant disease-causing bacteria so we can save millions of lives every year,” he says.
The G4 Cancer Cure, a new project developing a treatment for aggressive breast cancer, has recently joined the Umeå Biotech Incubator.
“We are extremely happy and look forward to some exciting times ahead. This is an important step for us in the development of our product,” says Associate Professor Nasim Sabouri, one of the project’s three owners.
Jennie Ekbeck, CEO of Umeå Biotech Incubator (UBI), has been nominated for the prestigious Nordic Startup Awards in the ‘Ecosystem Hero of the Year’ category.
“Wow! I’m so happy to be nominated! It is proof that all our work to create better conditions for life science development in Sweden has been appreciated,” she says.
QureTech Bio secures SEK 14 million investment – a very important milestone in their fight against antibiotic resistance
Venture capital company Nascent Invest has bought shares in Umeå-based QureTech Bio as part of a targeted new share issue. The multi-million SEK investment will provide long-term security for the Swedish life science company as it continues its work to discover and develop new solutions to combat antibiotic-resistant bacteria.
“This investment means we can develop faster and take on more employees. As a result, we can get our medicines to market faster and hopefully save more lives,” says Fredrik Almqvist, CEO of QureTech Bio.
A recruitment drive is underway at Diamyd Medical’s new vaccine facility in Umeå after the company announced it is moving production of the GAD65 protein, the active substance in the diabetes vaccine Diamyd, from abroad to Sweden.
“This move gives us greater control and more knowledge about our study drug. Personally it feels fantastic to be involved in building a vaccine facility from the ground up”, says Maja Johansson, Site Manager in Umeå.